The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
Low-dose THC beverages typically contain somewhere between 2 and 5 mg of THC per serving.…
A few dozen strangers answered one question, and here's what they told me. Cannabis rarely…
Federal officials admitted under oath at the DEA marijuana rescheduling hearing that the 54-year-old test…
Discover why Donald Trump lost the 2026 midterms, how the hemp and cannabis industries survived…
On October 29, Fox News ran a column by Dr. Marc Siegel, the network’s senior medical…
Is cannabis a miracle cure or a gateway to ruin? We break down the latest…